According to the results, EZF could regulate GIOP through several signaling pathways, such as PI3K-Akt, cancer, JAK-STAT, AGE-RAGE, HTLV-I infection, Hepatitis C, Epstein-Barr virus infection, ovarian steroidogenesis, C-type lectin receptor, FOXO, complement and coagulation cascades, transcriptional misregulation in cancer, insulin resistance, cushing syndrome, renal cell carcinoma, and microRNAs in cancer. This evidence concerns the gene SOAT1 and renal cell carcinoma.